|
Match
|
Document |
Document Title |
|
|
7390635 |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides...
|
|
|
7390491 |
Agents comprising midkine or an inhibitor thereof as active ingredient
Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
|
|
|
7390489 |
Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes , a hybridoma cell producing the monoclonal antibody, a test kit comprising...
|
|
|
7390486 |
PRO4381 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7384632 |
Agonist anti-trk-C monoclonal antibodies
The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such...
|
|
|
7384631 |
Methods of diagnosis and treatment by binding p75/AIRM1
p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells,...
|
|
|
7381412 |
Anti-TECK antibodies and methods of use therefor
The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also...
|
|
|
7381411 |
Aglyco products and methods of use
Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which...
|
|
|
7381410 |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides...
|
|
|
7381409 |
Antibodies specific for sclerostin and methods of screening and use therefor
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by...
|
|
|
7381407 |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods...
|
|
|
7378092 |
Immunogenic compositions for induction of anti-tumor immunity
The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at...
|
|
|
7374756 |
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent...
|
|
|
7371726 |
Neutralizing GDF8 epitope-based growth enhancing vaccine
The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new...
|
|
|
7371380 |
Anti-Cark antibodies and uses therefor
The invention provides isolated nucleic acids molecules, designated CARK nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors...
|
|
|
7371379 |
Dosages for treatment with anti-ErbB2 antibodies
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or...
|
|
|
7371378 |
Modified human IGF-IR antibodies
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention...
|
|
|
7371377 |
Antibodies to polypeptides homologous to VEGF and BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
7368543 |
Diagnosis and treatment of hepatic disorders
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration...
|
|
|
7368112 |
S. aureus fibrinogen binding protein gene
The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus CIfA protein are described. The nucleic acids...
|
|
|
7368111 |
Human antibodies specific for TGFβ2
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
|
|
|
7368106 |
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40...
|
|
|
7365054 |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to...
|
|
|
7364737 |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
7364733 |
Antibody to receptor on the surface of activated T-cells: ACT-4
The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and...
|
|
|
7364732 |
Method for treating inflammation
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
|
|
|
7361345 |
Anti-CD40 antibodies capable of blocking B-cell activation
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7361338 |
Methods to inhibit growth of prostate cancer cells
A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7361337 |
Antibodies against the PRO1754 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7357927 |
Death domain containing receptors
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
|
|
|
7357926 |
Antibodies against PRO1879 and the use thereof
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7354586 |
Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7354585 |
Methods of treating coagulapathic or thrombotic disorders
The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention...
|
|
|
7354583 |
Antibody-induced apoptosis
Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also...
|
|
|
7348001 |
Tie1-binding ligands
Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that...
|
|
|
7344716 |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
|
|
|
7339033 |
PRO1481
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7335748 |
RG1 antibodies and uses thereof
The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and...
|
|
|
7332582 |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
|
|
|
7332161 |
Treatment of disease with antibodies against high molecular weight kininogen domain 5
Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to...
|
|
|
7329737 |
Antibodies that bind hK-1
The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.
|
|
|
7329406 |
Methods of treating psoriasis with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7329404 |
Antibodies against PRO1310
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7326414 |
Antibodies to M-CSF
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also...
|
|
|
7326413 |
Antibodies against the PRO1434 polypeptide
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7323171 |
Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
|
|
|
7323170 |
Anti-CD80 antibodies
The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
|